{"id":91473,"date":"2026-01-01T08:16:10","date_gmt":"2026-01-01T08:16:10","guid":{"rendered":"https:\/\/www.europesays.com\/lv\/91473\/"},"modified":"2026-01-01T08:16:10","modified_gmt":"2026-01-01T08:16:10","slug":"peteris-apinis-ko-veselibas-aprupe-nesis-2026-gads-ipasi-metabola-sindroma-un-aptaukosanas-arstesana","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/lv\/91473\/","title":{"rendered":"P\u0113teris Apinis: Ko vesel\u012bbas apr\u016bp\u0113 nes\u012bs 2026. gads, \u012bpa\u0161i metabol\u0101 sindroma un aptauko\u0161an\u0101s \u0101rst\u0113\u0161an\u0101?"},"content":{"rendered":"

\" \"\/<\/p>\n

14:51, 31. decembris 2025<\/p>\n

P\u0101rskat\u012bju \u2013 ko prognoz\u0113ju\u0161i izcil\u0101kie vesel\u012bbas jomas pr\u0101ti, ko port\u0101li un diskusiju blogi \u2013 nek\u0101du revol\u016bciju neviens neprognoz\u0113. Vairums uzskata, ka izr\u0101viens b\u016bs telemedic\u012bn\u0101, vair\u0101k izmantos m\u0101ksl\u012bgo intelektu, veiksm\u012bg\u0101k apstr\u0101d\u0101s datus un lab\u0101k tos analiz\u0113s, par\u0101d\u012bsies da\u017eas jaunas vakc\u012bnas, tirg\u016b ien\u0101ks jauni medikamenti onkolo\u0123ij\u0101, psihiatrij\u0101 un atsevi\u0161\u0137u reto slim\u012bbu \u0101rst\u0113\u0161an\u0101, bet saist\u012bb\u0101 ar genomikas un biotehnolo\u0123iju att\u012bst\u012bbu liel\u0101ka uzman\u012bba tiks piev\u0113rsta personific\u0113tai medic\u012bnai. Tas noz\u012bm\u0113, ka \u0101rst\u0113\u0161anas pl\u0101ni tiks piel\u0101goti katra pacienta \u0123en\u0113tiskajam profilam, kas \u013caus efekt\u012bv\u0101k \u0101rst\u0113t slim\u012bbas. Ar tehnolo\u0123iju att\u012bst\u012bbu un jauniem p\u0113t\u012bjumiem, m\u0113s varam sagaid\u012bt pozit\u012bvas p\u0101rmai\u0146as, kas uzlabos cilv\u0113ku vesel\u012bbu un labkl\u0101j\u012bbu vis\u0101 pasaul\u0113. Par katru no \u0161iem pozit\u012bviem mekl\u0113jumiem un atradumiem var\u0113tu uzrakst\u012bt nelielu p\u0113t\u012bjumu bakalaura nosl\u0113guma darba apjom\u0101, bet diez vai maniem las\u012bt\u0101jiem tas liktos interesanti un saisto\u0161i. <\/p>\n

Las\u012bt\u0101kie
\n <\/p>\n

\"\"<\/p>\n

Kokteilis<\/p>\n

\n Ko vilkt Jaungada nakt\u012b? Astrologi sniedz prec\u012bzas nor\u0101des katrai zodiaka z\u012bmei\n <\/p>\n

<\/a><\/p>\n

\"\"<\/p>\n

Kokteilis<\/p>\n

\n Ko vilkt mugur\u0101, sagaidot Ugun\u012bg\u0101 Zirga gadu? Padomi katrai zodiaka z\u012bmei, lai piesaist\u012btu veiksmi un harmoniju\n <\/p>\n

<\/a><\/p>\n

\"\"<\/p>\n

\n Alvis Hermanis: Sveicin\u0101ti Vec\u0101 gada p\u0113d\u0113j\u0101 dien\u0101! Mums ir jaunumi!\n <\/p>\n

<\/a>
\n Las\u012bt citas zi\u0146as<\/a><\/p>\n

Un tom\u0113r \u2013 izskat\u0101s, ka 2026. gad\u0101 kaut k\u0101ds izr\u0101viens b\u016bs. N\u0101kamais gads sol\u0101s b\u016bt iz\u0161\u0137ir\u012bgs vair\u0101ku hronisku un gr\u016bti \u0101rst\u0113jamu slim\u012bbu terapij\u0101, nosl\u0113dzoties v\u0113rien\u012bgiem kl\u012bniskajiem p\u0113t\u012bjumiem un tirg\u016b ien\u0101kot jaunas paaudzes medikamentiem. Iesp\u0113jams, ka citi autori uzsvaru liktu uz pirmajiem narkolepsijas medikamentiem un m\u0113r\u0137tiec\u012bgu v\u0113\u017ea terapiju, bet man \u0161\u0137iet, ka noz\u012bm\u012bg\u0101kais izr\u0101viens b\u016bs metabolisk\u0101 sindroma \u0101rst\u0113\u0161an\u0101 jeb aptauko\u0161an\u0101s pand\u0113mijas mazin\u0101\u0161an\u0101 uz zemeslodes. Gaid\u0101ms Novo Nordisk kombin\u0113t\u0101 prepar\u0101ta CagriSema apstiprin\u0101jums, kas var\u0113tu b\u016bt v\u0113l efekt\u012bv\u0101ks par pa\u0161reiz\u0113jo Wegovy. CagriSema apvieno divas darb\u012bg\u0101s vielas, nodro\u0161inot sp\u0113c\u012bg\u0101ku s\u0101ta saj\u016btu nek\u0101 l\u012bdz\u0161in\u0113j\u0101s monoterapijas. Savuk\u0101rt Eli Lilly pl\u0101no pabeigt p\u0113t\u012bjumus un iesniegt apstiprin\u0101\u0161anai pirmo GLP-1 receptoru agonistu table\u0161u form\u0101, kas aizst\u0101s injekcijas. GLP-1 receptoru agonisti b\u016btu uzskat\u0101mi par medikamentiem, kas ne tikai pal\u012bdz zaud\u0113t svaru, bet ar\u012b uzlabo sirds un asinsvadu vesel\u012bbu. <\/p>\n

\u0160\u0137iet, pien\u0101cis laiks past\u0101st\u012bt \u2013 kas ir metabolais sindroms. Tas ir simptomu kopums, kas ir kop\u0113js iemesls sirds asinsvadu slim\u012bb\u0101m, insul\u012bna rezistencei un 2. tipa cukura diab\u0113tam, taukaino aknu slim\u012bbai, nieru mazsp\u0113jai, reproduktivit\u0101tes trauc\u0113jumiem, ar\u012b demencei un noveco\u0161anai k\u0101 t\u0101dai. \u0160ie simptomi, kas apvienojas metabolaj\u0101 sindrom\u0101 ir palielin\u0101ts viduk\u013ca apk\u0101rtm\u0113rs (centr\u0101l\u0101 aptauko\u0161an\u0101s), paaugstin\u0101ts asinsspiediens, paaugstin\u0101ts glikozes l\u012bmenis asin\u012bs, augsts triglicer\u012bdu l\u012bmenis, zems augsta bl\u012bvuma lipoprote\u012bnu (HDL) l\u012bmenis. Paties\u012bb\u0101 jau neviens tramvaj\u0101 vai darbaviet\u0101 nevar pateikt \u2013 k\u0101ds ir cita l\u012bdzbrauc\u0113ja vai kol\u0113\u0123a glikozes, triglicer\u012bdu vai lipoprote\u012bnu l\u012bmenis, bet to resnumu un v\u0113dera izm\u0113ru redz. Tad nu liel\u0101 m\u0113r\u0101 m\u0113s uzskat\u0101m, ka sipri resni cilv\u0113ki sirgst ar metabolo sindromu. Metabol\u0101 sindroma att\u012bst\u012bbu m\u0113s saist\u0101m gan ar ar \u0123en\u0113tiskiem, gan vides faktoriem, un to veicina nepietiekama fizisk\u0101 aktivit\u0101te, p\u0101rm\u0113r\u012bgs cukura un pies\u0101tin\u0101to tauku pat\u0113ri\u0146\u0161, \u0123en\u0113tiska predispoz\u012bcija, hormon\u0101las izmai\u0146as, stress un miega tr\u016bkums. <\/p>\n

CITI \u0160OBR\u012aD LASA<\/p>\n

Metabol\u0101 sindroms ir nopietns vesel\u012bbas st\u0101voklis, kas prasa uzman\u012bbu un akt\u012bvu r\u012bc\u012bbu. \u0100rsti r\u016bp\u0113s par saviem pacientiem \u2013 lai nov\u0113rstu un \u0101rst\u0113tu metabolo sindromu, iesaka izv\u0113l\u0113ties sabalans\u0113tu \u0113dienkarti, kas bag\u0101ta ar aug\u013ciem, d\u0101rze\u0146iem, pilngraudiem un vesel\u012bg\u0101m taukviel\u0101m. Protams, katrs \u0101rsts noz\u012bm\u0113 pacientiem ar\u012b sporto\u0161anu un fiziskas aktivit\u0101tes (s\u0101ksim visi sportot ar 1. janv\u0101ri!) \u2013 pastaigas, skrie\u0161anu, peld\u0113\u0161anu vai sporta sp\u0113les, kas pal\u012bdz\u0113tu uztur\u0113t vesel\u012bgu svaru. Svara zaud\u0113\u0161ana pat neliel\u0101 apm\u0113r\u0101 var iev\u0113rojami samazin\u0101t komplik\u0101ciju risku. Un tom\u0113r \u2013 bie\u017e\u0101k metabol\u0101 sindroma \u0101rst\u0113\u0161anai ir nepiecie\u0161ami medikamenti, bet nereti ar\u012b bariatrisk\u0101 \u0137irur\u0123ija. <\/p>\n

Atgriez\u012b\u0161os pie m\u016bsu st\u0101sta galven\u0101 varo\u0146a \u2013 2026. gada. Izskat\u0101s, ka 2026. gad\u0101 iez\u012bm\u0113s Pasaules Vesel\u012bbas organiz\u0101cija nosl\u0113gs un p\u0101rv\u0113rt\u0113s vair\u0101kus strat\u0113\u0123iskos m\u0113r\u0137us, lai palielin\u0101tu efekt\u012bvu aptauko\u0161an\u0101s profilakses un p\u0101rvald\u012bbas pas\u0101kumu p\u0101rkl\u0101jumu vis\u0101 pasaul\u0113. Galven\u0101 uzman\u012bba tiks no\u0146emta no individu\u0101laj\u0101m r\u012bc\u012bb\u0101m, un piev\u0113rsta sist\u0113misk\u0101m izmai\u0146\u0101m, mazinot stigmu un uzlabojot piek\u013cuvi modern\u0101m \u0101rst\u0113\u0161anas metod\u0113m. 2026. gada 4. mart\u0101 Pasaules Aptauko\u0161an\u0101s diena tiks atz\u012bm\u0113ta ar saukli \u201cMaini st\u0101stu\u201d, un aicin\u0101s 8 miljardus zemeslodes iedz\u012bvot\u0101ju p\u0101rskat\u012bt savus priek\u0161status par aptauko\u0161anos k\u0101 hronisku slim\u012bbu. Savuk\u0101rt no 15. l\u012bdz 17. j\u016blijam Meksik\u0101 notiks Starptautiskais aptauko\u0161an\u0101s kongress. Konference Meksik\u0101 \u012bpa\u0161u uzman\u012bbu piev\u0113rs\u012bs tam, lai jaunie peror\u0101lie GLP-1 medikamenti ekonomiski pamatoti tiktu integr\u0113ti valstu vesel\u012bbas apr\u016bpes sist\u0113m\u0101s. Tas attiecas ar\u012b uz Latviju, un n\u0101ksies Vesel\u012bbas ministrijai mekl\u0113t l\u012bdzek\u013cus lai kompens\u0113tu \u0161os medikamentus cilv\u0113kiem ar metabolo sindromu. <\/p>\n

Tiks izdota jauna Eiropas Aptauko\u0161an\u0101s p\u0113tniec\u012bbas asoci\u0101cijas (EASO) medikamentoz\u0101s p\u0101rvald\u012bbas algoritma redakcija. Eiropas m\u0113roga p\u0113tniec\u012bbas programma koncentr\u0113sies uz nov\u0101rt\u0101 atst\u0101tiem aptauko\u0161an\u0101s c\u0113lo\u0146iem un inovat\u012bviem meh\u0101nismiem t\u0101s nov\u0113r\u0161anai.<\/p>\n

Nav viegli to izskaidrot, bet 2026. gadam pasaule pl\u0101no p\u0101riet no \u201cvaino\u0161anas kult\u016bras\u201d uz sist\u0113misku pieeju. Tas ietver pils\u0113tvides pl\u0101no\u0161anu, kas veicina kust\u012bbu, un stingr\u0101kus noteikumus p\u0101rtikas r\u016bpniec\u012bbai attiec\u012bb\u0101 uz cukura un tauku saturu produktos. Par to, par ko esam c\u012bn\u012bju\u0161ies daudzus gadus ar ra\u017eot\u0101jiem un Finan\u0161u ministrijas ier\u0113d\u0146iem, tagad ra\u017eot\u0101jiem un ier\u0113d\u0146iem n\u0101ksies piek\u0101pties Eiropas savien\u012bbas strat\u0113\u0123ijai \u2013 maks\u0101t liel\u0101kus nodok\u013cus par produktiem, kas satur cukurus un pies\u0101tin\u0101tas tauksk\u0101bes. <\/p>\n

Metabol\u0101 sindroma \u0101rst\u0113\u0161ana ir k\u013cuvusi par aktu\u0101lu t\u0113mu, \u0146emot v\u0113r\u0101 pieaugo\u0161o saslimst\u012bbu. T\u0101tad 2026. gad\u0101 m\u0113s varam sagaid\u012bt jaunu medikamentu par\u0101d\u012b\u0161anos table\u0161u form\u0101, kas var\u0113tu b\u016btiski uzlabot \u0101rst\u0113\u0161anas iesp\u0113jas. Viens no noz\u012bm\u012bg\u0101kajiem jaunajiem medikamentiem metabol\u0101 sindroma \u0101rst\u0113\u0161anai ir orforglipron, kas ir jaun\u0101s paaudzes GLP-1 receptoru agonists. Tas ir paredz\u0113ts svara zudumam un uzlabo insul\u012bna jut\u012bbu, kas ir b\u016btiski metabol\u0101 sindroma gad\u012bjum\u0101. \u0160is medikaments ir izstr\u0101d\u0101ts, lai nodro\u0161in\u0101tu efekt\u012bv\u0101ku svara zudumu sal\u012bdzin\u0101jum\u0101 ar eso\u0161ajiem prepar\u0101tiem.
Tirg\u016b ir pieejami ar\u012b SGLT2 inhibitori, un \u0161ogad par\u0101d\u012bsies ar\u012b jauni \u0161\u012bs grupas medikamenti, kas pal\u012bdz\u0113s kontrol\u0113t glikozes l\u012bmeni asin\u012bs un veicin\u0101s svara zudumu. \u0160ie medikamenti, piem\u0113ram, empagliflozin un canagliflozin, jau ir pier\u0101d\u012bju\u0161i savu efektivit\u0101ti.<\/p>\n

Jauni p\u0113t\u012bjumi koncentr\u0113jas uz medikamentiem, kas ietekm\u0113 tauku metabolismu un insul\u012bna rezistenci. Es dom\u0101ju, ka jau 2026. gad\u0101 glob\u0101laj\u0101 p\u0113tniec\u012bb\u0101 \u2013 p\u0113t\u012bjumos ar cilv\u0113kiem \u2013par\u0101d\u012bties ar\u012b kombin\u0113ti medikamenti, kas apvieno vair\u0101kas akt\u012bv\u0101s vielas, piem\u0113ram, GLP-1 receptoru agonistus ar SGLT2 inhibitoriem, lai nodro\u0161in\u0101tu siner\u0123isku efektu. \u0160\u0101das kombin\u0101cijas pied\u0101v\u0101s lab\u0101kus rezult\u0101tus pacientiem ar metabol\u0101 sindroma paz\u012bm\u0113m, k\u0101 ar\u012b samazin\u0101s blak\u0146u risku. Cer\u0113sim, ka mana prognoze piepild\u012bsies, un 2026. gads k\u013c\u016bs par iz\u0161\u0137iro\u0161o gadu jaunu table\u0161u formas medikamentu ien\u0101k\u0161anai tirg\u016b metabol\u0101 sindroma \u0101rst\u0113\u0161anai. Jaun\u0101s terapijas, piem\u0113ram, GLP-1 receptoru agonisti un potenci\u0101l\u0101s kombin\u0113t\u0101s terapijas, sol\u0101s uzlabot pacientu dz\u012bves kvalit\u0101ti un samazin\u0101t ar metabolo sindromu saist\u012bto komplik\u0101ciju risku. <\/p>\n

Un k\u0101 tas attieksies uz mani? \u2013 \u0161\u0101di man jaut\u0101s katrs resns pacients, kur\u0161 ne \u0161obr\u012bd var at\u013cauties ieg\u0101d\u0101ties modernos medikamentus, ne n\u0101kotn\u0113 to sp\u0113s. <\/p>\n

Man \u0161\u0137iet, ka tablet\u0113s lietojamo medikamentu tirgus metabol\u0101 sindroma un aptauko\u0161an\u0101s \u0101rst\u0113\u0161anai piedz\u012bvos strauju izaugsmi, pateicoties zem\u0101k\u0101m ra\u017eo\u0161anas izmaks\u0101m sal\u012bdzin\u0101jum\u0101 ar injekcij\u0101m un vienk\u0101r\u0161\u0101kai lo\u0123istikai. Table\u0161u form\u0101ts neprasa \u201caukstuma \u0137\u0113des\u201d lo\u0123istiku (uzglab\u0101\u0161anu ledusskap\u012b). Vismaz 2026. gad\u0101 s\u0101kotn\u0113j\u0101s cenas jaunajiem patent\u0113tiem medikamentiem, piem\u0113ram, orforglipron, b\u016bs augstas, bet glob\u0101l\u0101 konkurence un ra\u017eo\u0161anas apjomu pieaugums ilgtermi\u0146\u0101 veicin\u0101s cenu samazin\u0101\u0161anos. Pa\u0161laik GLP-1 receptoru agonistu tirgus v\u0113rt\u012bba p\u0101rsniedz 50 miljardus ASV dol\u0101ru, un prognozes liecina, ka \u0161is apjoms tr\u012bsk\u0101r\u0161osies l\u012bdz 2030. gadam. Pieejam\u012bbu 2026. gad\u0101 noteiks ne tikai cena, bet ar\u012b tas, vai Vesel\u012bbas ministrija iek\u013caus \u0161os medikamentus kompens\u0113jamo sarakst\u0101.<\/p>\n

No netie\u0161iem avotiem ir zin\u0101ms, ka \u0136\u012bn\u0101 un Indij\u0101 farm\u0101cijas uz\u0146\u0113mumi str\u0101d\u0101 pie sav\u0101m peror\u0101lo GLP-1 versij\u0101m, kas noteikti b\u016bs l\u0113t\u0101kas par ASV un Eiropas ra\u017eot\u0101ju z\u0101l\u0113m, tiesa, p\u0113t\u012bjumu l\u012bmenis ar\u012b b\u016bs zem\u0101ks. Ja tie\u0161\u0101m 2026. gad\u0101 Indijas un \u0136\u012bnas uz\u0146\u0113mumi savus peror\u0101los medikamentus 3. pasaules valst\u012bs s\u0101ks izplat\u012bt, tie non\u0101ks ar\u012b pie mums ar interneta tirgu. Tas rad\u012bs diezgan daudz risku un probl\u0113mu, pie kam b\u016bs gr\u016bti identific\u0113t \u012bstus medikamentus no viltojumiem. <\/p>\n

Glob\u0101l\u0101 aptauko\u0161an\u0101s pand\u0113mija ir saist\u012bta ar sare\u017e\u0123\u012btiem soci\u0101liem, ekonomiskiem un vides faktoriem, un 2026. gad\u0101 tiks izstr\u0101d\u0101tas da\u017e\u0101das iniciat\u012bvas, lai risin\u0101tu \u0161o probl\u0113mu, koncentr\u0113joties uz da\u017e\u0101d\u0101m iedz\u012bvot\u0101ju grup\u0101m, tostarp sieviet\u0113m un v\u012brie\u0161iem, b\u0113rniem un veciem \u013caud\u012bm, k\u0101 ar\u012b uz profilaksi, prevenciju, sportisk\u0101m aktivit\u0101t\u0113m un uztura politiku. <\/p>\n

J\u0101dom\u0101, ka tiks uzsv\u0113rta sievie\u0161u vesel\u012bba, \u0146emot v\u0113r\u0101, ka aptauko\u0161an\u0101s var ietekm\u0113t reprodukt\u012bvo vesel\u012bbu, gr\u016btniec\u012bbu un psiholo\u0123isko labkl\u0101j\u012bbu. PVO izstr\u0101d\u0101 programmu, kas pal\u012bdz\u0113s sieviet\u0113m piek\u013c\u016bt vesel\u012bg\u0101m p\u0101rtikas izv\u0113l\u0113m un veicin\u0101s fiziskas aktivit\u0101tes, \u012bpa\u0161i gr\u016btniec\u012bbas un p\u0113cdzemd\u012bbu period\u0101. V\u012brie\u0161u aptauko\u0161an\u0101s probl\u0113ma k\u0101 viem\u0113r tiek maz\u0101k uzsv\u0113rta, ta\u010du paredz\u0113ts izstr\u0101d\u0101t specifiskas kampa\u0146as, kas v\u0113rstas uz v\u012brie\u0161u dz\u012bvesveidu, veicinot fizisk\u0101s aktivit\u0101tes un vesel\u012bgu uzturu, k\u0101 ar\u012b uzsverot emocion\u0101lo vesel\u012bbu un v\u012brie\u0161u stigmu attiec\u012bb\u0101 uz uztura un svara probl\u0113m\u0101m.<\/p>\n

Glob\u0101li tiks ieviestas programmas, kas v\u0113rstas uz b\u0113rniem un pusaud\u017eiem, lai veicin\u0101tu vesel\u012bgu uzturu un fizisk\u0101s aktivit\u0101tes jau agr\u012bn\u0101 vecum\u0101, t\u0101d\u0113j\u0101di samazinot aptauko\u0161an\u0101s risku n\u0101kotn\u0113. Diem\u017e\u0113l Latvij\u0101, kam\u0113r vien Izgl\u012bt\u012bbas un zin\u0101tnes ministrij\u0101 darbojas Izgl\u012bt\u012bbas valsts kvalit\u0101tes dienests (pati birokr\u0101tisk\u0101k\u0101 strukt\u016bra valst\u012b, kas vis\u0101di pretojas b\u0113rnu fiziskaj\u0101m aktivit\u0101t\u0113m) tuv\u0101kaj\u0101 laik\u0101 nek\u0101di uzlabojumi nav gaid\u0101mi un tre\u0161da\u013ca Latvijas b\u0113rnu ir un b\u016bs ar lieko svaru vai aptauko\u0161anos. Valsts uzdevums b\u016btu rast iniciat\u012bvas, kas veicina sportu un fizisk\u0101s aktivit\u0101tes k\u0101 svar\u012bgu ikdienas dz\u012bves sast\u0101vda\u013cu. Tas ietvertu piek\u013cuves uzlabo\u0161anu sporta infrastrukt\u016brai un iesp\u0113ju piedal\u012bties sporta aktivit\u0101t\u0113s visiem sabiedr\u012bbas sl\u0101\u0146iem. Un v\u0113l Latvijai der\u0113tu str\u0101d\u0101t pie politikas, kas veicin\u0101tu vesel\u012bgas p\u0101rtikas lieto\u0161anu un mazin\u0101tus piek\u013cuvi nevesel\u012bgai p\u0101rtikai. \u0160\u0101da politika ietvertu stingr\u0101kus regul\u0113jumus par p\u0101rtikas produktu mar\u0137\u0113\u0161anu, rekl\u0101mu un cenu politiku.
Tiesa, v\u0113l\u0113\u0161anu gad\u0101 Latvijas vald\u012bba nem\u0113dz izcelties ar gudriem l\u0113mumiem un saprotamu vesel\u012bbas politiku, bet b\u016btu j\u0101cen\u0161as vesel\u012bbas jomu k\u0101 strat\u0113\u0123iju \u201ciebarot\u201d tiem, kas v\u0113las tikt iev\u0113l\u0113ti n\u0101kamaj\u0101 Saeim\u0101. <\/p>\n","protected":false},"excerpt":{"rendered":"14:51, 31. decembris 2025 P\u0101rskat\u012bju \u2013 ko prognoz\u0113ju\u0161i izcil\u0101kie vesel\u012bbas jomas pr\u0101ti, ko port\u0101li un diskusiju blogi \u2013…\n","protected":false},"author":2,"featured_media":91474,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[23,28,29,32,33,22,30,31,35,39,38,36,37,34,40,20,26,27,24,25,21],"class_list":{"0":"post-91473","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-aktualitates","8":"tag-aktualitates","9":"tag-breaking-news","10":"tag-breakingnews","11":"tag-featured-news","12":"tag-featurednews","13":"tag-headlines","14":"tag-latest-news","15":"tag-latestnews","16":"tag-latvia","17":"tag-latvian","18":"tag-latviesu","19":"tag-latviesu-valoda","20":"tag-latviesuvaloda","21":"tag-latvija","22":"tag-lv","23":"tag-news","24":"tag-popularakas-zinas","25":"tag-popularakaszinas","26":"tag-top-stories","27":"tag-topstories","28":"tag-zinas"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lv\/115818855379163567","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/91473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/comments?post=91473"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/91473\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media\/91474"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media?parent=91473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/categories?post=91473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/tags?post=91473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}